The Danish drugmaker will start selling a pill version of its Wegovy weight-loss medicine in January, after [securing ...

As Novo Nordisk’s FDA-approved Wegovy pill sets up a high-stakes comeback, should NVO be back on investors’ radar now?

As Novo Nordisk’s weight-loss pill Wegovy (semaglutide) readies for a launch in the United States early January, it will be a ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

Pharmaceutical giants like Lilly and Nordisk are battling for dominance in India’s weight-loss market with price cuts and ...

Hyderabad: Global pharma heavyweights Eli Lilly and Novo Nordisk are racing to lock in market leadership in India’s blooming ...

Eli Lilly is the clear leader in the burgeoning weight loss market. Its lineup and pipeline put it well ahead of even its ...

The drugs' high prices, along with spotty insurance coverage, have left them out of reach for many Americans. Read more at ...

Major stock indexes ended higher for a fourth straight session Tuesday, with the S&P 500 setting a fresh closing record, ...

U.S. regulators on Monday gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity. The U.S. Food and Drug Administration’s ...

Weight loss isn't the only change Individuals who are taking a GLP-1 weight loss medicine are seeing. They also tend to spend less on groceries. That's the assessment from a recently published study ...

India's obesity drug market is experiencing rapid growth, driven by rising lifestyle diseases and the launch of blockbuster ...